Normin Health was founded by Dr. Wendong Chen in 2012. Since then, Normin Health started the first observational study using hospital data to assess treatment outcomes and hospital costs associated with first-line and second-line chemotherapies in patients with non-squamous non-small cell lung cancer. With the huge success of this very first project, Normin Health has built up a highly specialized team to conduct real-world studies and develop health economic models to meet the evidence needs of developing market access strategies, supporting reimbursement submissions, and supporting commercial promotions. Normin Health has provided services to many international pharmaceutical and medical devices companies. These companies include Eli Lilly, Xian Janssen, BMS, Novartis Oncology, Gilead, Celgene, J &J, and BD. Normin Health has been highly recognized by these clients for professionalism, innovation, and quality. Normin Health is also actively developing new business to better meet market access needs. These new businesses include the development of mobile phone APP communication tool for better communications of the clinical and economic values of medical products and the development of patient follow-up mobile phone APP to fill the current real-world data gaps.